search
Back to results

Dose Ranging Study of the Efficacy and Tolerability of Tonabersat in the Prophylaxis of Migraine Headache (TEMPUS)

Primary Purpose

Migraine Without Aura, Migraine With Aura

Status
Completed
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
Tonabersat
Tonabersat
Placebo
Sponsored by
Minster Research Ltd
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Migraine Without Aura

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • A signed and dated written informed consent is obtained prior to participation.
  • Male or female patients between 18-65 years of age who are ambulatory and able to travel to the clinic; women of childbearing potential must be using a reliable form of contraception (contraceptive pill or double-barrier contraception - partner using condom and patient using spermicide, diaphragm, intra-uterine device or contraceptive sponge) for at least 2 months prior to enrolment and have a negative pregnancy test at screening. Women of childbearing potential must continue to practice birth control during and for at least two months after the study
  • Patients with an established history of migraine of at least 1 year with or without aura meeting the diagnostic criteria of the International Classification of Headache Disorders - Edition 2.
  • Patients should have experienced an average of at least 4 migraine attacks per month over the 3 months prior to entering the trial and at least 3 migraine attacks during the baseline period. Patients should report a maximum of 12 migraine headache days during the baseline period.

Exclusion Criteria:

  • Patients with an onset of migraine according to the above criteria at age 50 years or more.
  • Patients who experience > 12 headache days during the baseline period.
  • Patients who have failed to respond to adequate trials of 3 or more preventive medications.
  • Overuse of acute migraine treatments defined as ≥ 15 medication days per month of which no more than 9 days includes ergots or triptans.
  • Any woman who is pregnant, lactating or not using medically acceptable contraception.
  • Patients taking other medications used as prophylaxis for migraine including topiramate, methysergide, anti-spasticity agents (e.g. tizanidine) and new generation antipsychotics (e.g. olanzapine) currently or within 1 month prior to entry to the trial.
  • Patients taking any of the following medications: beta-blockers, tricyclic antidepressants, antiepileptic drugs, calcium channel blockers, or monoamine oxidase inhibitors during or within 1 month prior to the study; daily oral NSAIDs, daily paracetamol, high dose magnesium supplements (600 mg/day), daily multivitamin preparations containing more than 10 mg riboflavin, daily use of oral corticosteroids, herbal preparations (e.g. feverfew, butterwort and St John's Wort). Patients who have received parenteral administration of botulinum toxin within the previous 3 months will also be excluded.
  • Patients who, in the opinion of the Investigator, have significant cerebrovascular disease (e.g. transient ischemic attacks, stroke) or significant cardiovascular disease within 30 days prior to screening.
  • Patients suffering from any significant psychiatric disorder.
  • Patient has a concomitant disease or condition that, in the opinion of the Investigator, could interfere with the conduct of the study or could put the patient at unacceptable risk.
  • Patients with renal dysfunction, defined as a serum creatinine of greater then 2 mg/dL.
  • Patients with hepatic dysfunction defined as a liver function test (AST, ALT, alkaline phosphatase, bilirubin) of greater than twice the upper limit of normal for their age group.
  • Patients with known alcohol or other substance abuse.
  • Patient is a participating Investigator, sub-investigator, study coordinator, or employee of a participating Investigator, or is an immediate family member of the aforementioned.
  • Any factor, which in the opinion of the Investigator would jeopardize the evaluation or safety or be associated with poor adherence to the protocol.
  • The patient's primary care physician recommends the patient should not take part in the study.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm 3

    Arm Type

    Experimental

    Experimental

    Placebo Comparator

    Arm Label

    1

    2

    3

    Arm Description

    Outcomes

    Primary Outcome Measures

    Reduction in the mean monthly number of migraine attacks over the last 2 months of the treatment period.
    Safety and tolerability: incidence of all AEs, serious adverse events (SAEs) and those leading to withdrawal of study medication, review of laboratory data, including hematology, biochemistry, and urinalysis, physical examinations, and vital signs.
    Assessment of population pharmacokinetics for tonabersat - blood samples will be collected from a sub-population of patients

    Secondary Outcome Measures

    • Reduction in mean monthly migraine attacks during the last 4 months of the treatment period and during each month of the treatment period.
    • Proportion of patients defined as a responder i.e. difference between treatment groups in the number of patients with a reduction of at least 50% in the mean monthly frequency of migraine attacks during defined periods.
    • Reduction in mean monthly migraine headache days i.e. the difference between the two treatment groups in the reduction from baseline during defined periods
    • Proportion of patients defined as a responder i.e. difference between treatment groups in the number of patients with a reduction of at least 50% in the mean monthly number of migraine headache days during defined periods
    • Reduction in mean monthly consumption (number of days per month) of rescue medication during defined periods
    • Onset of action (defined as first monthly period for which a significant difference between treatment groups is observed and is then maintained over the rest of the treatment period).
    • Difference between treatment groups in the maximum severity of migraine attacks occurring during defined periods
    • Summary of the Migraine Disability Assessment Score (MIDAS) assessments.

    Full Information

    First Posted
    September 24, 2007
    Last Updated
    March 30, 2009
    Sponsor
    Minster Research Ltd
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT00534560
    Brief Title
    Dose Ranging Study of the Efficacy and Tolerability of Tonabersat in the Prophylaxis of Migraine Headache
    Acronym
    TEMPUS
    Official Title
    Multi-Centre, Parallel Group, Double-Blind, Placebo Controlled, Dose Ranging Study of the Efficacy and Tolerability of Tonabersat in the Prophylaxis of Migraine Headache and Open Label Extension
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    March 2009
    Overall Recruitment Status
    Completed
    Study Start Date
    October 2007 (undefined)
    Primary Completion Date
    November 2008 (Actual)
    Study Completion Date
    March 2009 (Actual)

    3. Sponsor/Collaborators

    Name of the Sponsor
    Minster Research Ltd

    4. Oversight

    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    Primary objective: To investigate the efficacy and tolerability of two doses of tonabersat compared to placebo in the prophylaxis of migraine headache and to evaluate the longer term tolerability of tonabersat in an open label extension. Secondary objective(s): To obtain further data on the efficacy and dose response of tonabersat; To extend the safety and tolerability database of tonabersat; To obtain data on the pharmacokinetics of tonabersat.
    Detailed Description
    A multi-centre, double-blind, placebo controlled, randomized, parallel group, dose ranging study to investigate the efficacy and tolerability of two different target doses of tonabersat and placebo in the prophylaxis of migraine. Following initial screening patients will enter a 4 week baseline assessment period, prior to randomization to one of three treatment groups. Subsequently patients will be allocated, according to the predetermined randomization schedule, to treatment with placebo or a target dose of tonabersat 40 mg/day or 80 mg/day in a 20 week treatment period. A dose titration regimen will be employed over a period of 4 weeks and treatment will then be maintained for a further 16 weeks. During the baseline assessment period and the treatment period patients will maintain a daily record (diary data) of the occurrence of migraine headache, the severity of an attack, the presence/absence of a preceding aura, other symptoms associated with the migraine and details of the use of rescue medication (patients will be permitted to use their usual symptomatic/acute treatment as rescue medication throughout the trial). Patients will attend the clinic for assessment and collection of blood and urine samples for laboratory analysis, and a sub-population of patients will participate in a pharmacokinetic study. A total of 7 visits are planned during the randomized double-blind treatment period. On completion of the randomized double-blind treatment period all patients will be offered the opportunity to enter an open label extension study where all patients receive tonabersat. A dose titration regimen will be employed over a period of 1 month and the final assigned dose of tonabersat (40, 60 or 80 mg/day) will be continued for the next 12 months. During the open label extension patients will attend the clinic for regular assessment of migraine status and safety. A total of 5 visits are planned.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Migraine Without Aura, Migraine With Aura

    7. Study Design

    Primary Purpose
    Prevention
    Study Phase
    Phase 2
    Interventional Study Model
    Parallel Assignment
    Masking
    ParticipantInvestigatorOutcomes Assessor
    Allocation
    Randomized
    Enrollment
    542 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    1
    Arm Type
    Experimental
    Arm Title
    2
    Arm Type
    Experimental
    Arm Title
    3
    Arm Type
    Placebo Comparator
    Intervention Type
    Drug
    Intervention Name(s)
    Tonabersat
    Other Intervention Name(s)
    SB220453
    Intervention Description
    Tablets, 4 week dose titration and 16 weeks treatment at target dose of 40 mg per day
    Intervention Type
    Drug
    Intervention Name(s)
    Tonabersat
    Other Intervention Name(s)
    SB220453
    Intervention Description
    Tablets: 4 week titration and 16 weeks at target dose of 80 mg per day
    Intervention Type
    Drug
    Intervention Name(s)
    Placebo
    Intervention Description
    Tablets; 4 week dose titration with 16 weeks at target dose
    Primary Outcome Measure Information:
    Title
    Reduction in the mean monthly number of migraine attacks over the last 2 months of the treatment period.
    Time Frame
    4 weeks baseline and 20 weeks DB treatment
    Title
    Safety and tolerability: incidence of all AEs, serious adverse events (SAEs) and those leading to withdrawal of study medication, review of laboratory data, including hematology, biochemistry, and urinalysis, physical examinations, and vital signs.
    Time Frame
    4 weeks baseline, 20 weeks DB treatment and 13 months open label extension
    Title
    Assessment of population pharmacokinetics for tonabersat - blood samples will be collected from a sub-population of patients
    Time Frame
    20 weeks DB treatment
    Secondary Outcome Measure Information:
    Title
    • Reduction in mean monthly migraine attacks during the last 4 months of the treatment period and during each month of the treatment period.
    Time Frame
    4 weeks baseline and 20 weeks DB treatment
    Title
    • Proportion of patients defined as a responder i.e. difference between treatment groups in the number of patients with a reduction of at least 50% in the mean monthly frequency of migraine attacks during defined periods.
    Time Frame
    4 week baseline and 20 weeks DB treatment
    Title
    • Reduction in mean monthly migraine headache days i.e. the difference between the two treatment groups in the reduction from baseline during defined periods
    Time Frame
    4 weeks baseline and 20 weeks DB treatment
    Title
    • Proportion of patients defined as a responder i.e. difference between treatment groups in the number of patients with a reduction of at least 50% in the mean monthly number of migraine headache days during defined periods
    Time Frame
    4 weeks baseline and 20 weeks DB treatment
    Title
    • Reduction in mean monthly consumption (number of days per month) of rescue medication during defined periods
    Time Frame
    4 weeks baseline and 20 weeks DB treatment
    Title
    • Onset of action (defined as first monthly period for which a significant difference between treatment groups is observed and is then maintained over the rest of the treatment period).
    Time Frame
    4 weeks baseline and 20 weeks DB treatment
    Title
    • Difference between treatment groups in the maximum severity of migraine attacks occurring during defined periods
    Time Frame
    4 weeks baseline and 20 weeks DB treatment
    Title
    • Summary of the Migraine Disability Assessment Score (MIDAS) assessments.
    Time Frame
    4 weeks baseline, 20 weeks DB treatment and 13 months open label extension

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    65 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: A signed and dated written informed consent is obtained prior to participation. Male or female patients between 18-65 years of age who are ambulatory and able to travel to the clinic; women of childbearing potential must be using a reliable form of contraception (contraceptive pill or double-barrier contraception - partner using condom and patient using spermicide, diaphragm, intra-uterine device or contraceptive sponge) for at least 2 months prior to enrolment and have a negative pregnancy test at screening. Women of childbearing potential must continue to practice birth control during and for at least two months after the study Patients with an established history of migraine of at least 1 year with or without aura meeting the diagnostic criteria of the International Classification of Headache Disorders - Edition 2. Patients should have experienced an average of at least 4 migraine attacks per month over the 3 months prior to entering the trial and at least 3 migraine attacks during the baseline period. Patients should report a maximum of 12 migraine headache days during the baseline period. Exclusion Criteria: Patients with an onset of migraine according to the above criteria at age 50 years or more. Patients who experience > 12 headache days during the baseline period. Patients who have failed to respond to adequate trials of 3 or more preventive medications. Overuse of acute migraine treatments defined as ≥ 15 medication days per month of which no more than 9 days includes ergots or triptans. Any woman who is pregnant, lactating or not using medically acceptable contraception. Patients taking other medications used as prophylaxis for migraine including topiramate, methysergide, anti-spasticity agents (e.g. tizanidine) and new generation antipsychotics (e.g. olanzapine) currently or within 1 month prior to entry to the trial. Patients taking any of the following medications: beta-blockers, tricyclic antidepressants, antiepileptic drugs, calcium channel blockers, or monoamine oxidase inhibitors during or within 1 month prior to the study; daily oral NSAIDs, daily paracetamol, high dose magnesium supplements (600 mg/day), daily multivitamin preparations containing more than 10 mg riboflavin, daily use of oral corticosteroids, herbal preparations (e.g. feverfew, butterwort and St John's Wort). Patients who have received parenteral administration of botulinum toxin within the previous 3 months will also be excluded. Patients who, in the opinion of the Investigator, have significant cerebrovascular disease (e.g. transient ischemic attacks, stroke) or significant cardiovascular disease within 30 days prior to screening. Patients suffering from any significant psychiatric disorder. Patient has a concomitant disease or condition that, in the opinion of the Investigator, could interfere with the conduct of the study or could put the patient at unacceptable risk. Patients with renal dysfunction, defined as a serum creatinine of greater then 2 mg/dL. Patients with hepatic dysfunction defined as a liver function test (AST, ALT, alkaline phosphatase, bilirubin) of greater than twice the upper limit of normal for their age group. Patients with known alcohol or other substance abuse. Patient is a participating Investigator, sub-investigator, study coordinator, or employee of a participating Investigator, or is an immediate family member of the aforementioned. Any factor, which in the opinion of the Investigator would jeopardize the evaluation or safety or be associated with poor adherence to the protocol. The patient's primary care physician recommends the patient should not take part in the study.
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Richard Lipton, MD
    Organizational Affiliation
    Montefiore Medical Center Headache Unit
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Citations:
    PubMed Identifier
    11167908
    Citation
    Tfelt-Hansen P, Block G, Dahlof C, Diener HC, Ferrari MD, Goadsby PJ, Guidetti V, Jones B, Lipton RB, Massiou H, Meinert C, Sandrini G, Steiner T, Winter PB; International Headache Society Clinical Trials Subcommittee. Guidelines for controlled trials of drugs in migraine: second edition. Cephalalgia. 2000 Nov;20(9):765-86. doi: 10.1046/j.1468-2982.2000.00117.x. No abstract available.
    Results Reference
    background
    PubMed Identifier
    11128819
    Citation
    Grosser K, Oelkers R, Hummel T, Geisslinger G, Brune K, Kobal G, Lotsch J. Olfactory and trigeminal event-related potentials in migraine. Cephalalgia. 2000 Sep;20(7):621-31. doi: 10.1111/j.1468-2982.2000.00094.x.
    Results Reference
    background
    PubMed Identifier
    10219926
    Citation
    Hu XH, Markson LE, Lipton RB, Stewart WF, Berger ML. Burden of migraine in the United States: disability and economic costs. Arch Intern Med. 1999 Apr 26;159(8):813-8. doi: 10.1001/archinte.159.8.813.
    Results Reference
    background
    PubMed Identifier
    10496257
    Citation
    Stewart WF, Lipton RB, Whyte J, Dowson A, Kolodner K, Liberman JN, Sawyer J. An international study to assess reliability of the Migraine Disability Assessment (MIDAS) score. Neurology. 1999 Sep 22;53(5):988-94. doi: 10.1212/wnl.53.5.988.
    Results Reference
    background

    Learn more about this trial

    Dose Ranging Study of the Efficacy and Tolerability of Tonabersat in the Prophylaxis of Migraine Headache

    We'll reach out to this number within 24 hrs